Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches
Jasimuddin Ahamed, Jeffrey Laurence
Jasimuddin Ahamed, Jeffrey Laurence
Published August 1, 2022
Citation Information: J Clin Invest. 2022;132(15):e161167. https://doi.org/10.1172/JCI161167.
View: Text | PDF
Review

Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches

  • Text
  • PDF
Abstract

SARS-CoV-2–infected individuals may suffer a multi–organ system disorder known as “long COVID” or post-acute sequelae of SARS-CoV-2 infection (PASC). There are no standard treatments, the pathophysiology is unknown, and incidence varies by clinical phenotype. Acute COVID-19 correlates with biomarkers of systemic inflammation, hypercoagulability, and comorbidities that are less prominent in PASC. Macrovessel thrombosis, a hallmark of acute COVID-19, is less frequent in PASC. Female sex at birth is associated with reduced risk for acute COVID-19 progression, but with increased risk of PASC. Persistent microvascular endotheliopathy associated with cryptic SARS-CoV-2 tissue reservoirs has been implicated in PASC pathology. Autoantibodies, localized inflammation, and reactivation of latent pathogens may also be involved, potentially leading to microvascular thrombosis, as documented in multiple PASC tissues. Diagnostic assays illuminating possible therapeutic targets are discussed.

Authors

Jasimuddin Ahamed, Jeffrey Laurence

×

Figure 1

Clinical signs and symptoms distinguish long COVID (PASC) from acute COVID-19.

Options: View larger image (or click on image) Download as PowerPoint
Clinical signs and symptoms distinguish long COVID (PASC) from acute COV...
(A) Common clinical signs and symptoms as well as comorbidities and other cofactors for disease progression distinguish long COVID, also known as PASC, from acute COVID-19. In particular, female sex at birth is linked to a higher incidence of PASC, while male sex at birth is a risk factor for acute COVID-19 progression. Multiple metabolic and cardiovascular risk factors exacerbate acute COVID-19. Overall, age, BMI, and prior respiratory or cardiovascular history do not affect the incidence of PASC but may influence its clinical phenotype. (B) An acute thromboinflammatory process characterizes acute COVID-19. Clinical progression parallels biomarkers of EC injury and a hyperinflammatory state, including enhanced release of proinflammatory cytokines and chemokines, activation of complement and coagulation cascades, platelet activation, NETosis, and, ultimately, hypoxia. IFN-I signals can promote an antiviral response via MxA and exacerbate inflammation. AKI, acute kidney injury; AMI, acute myocardial infarction; ANC, absolute neutrophil count; ATN, acute tubular necrosis; CRP, C-reactive protein; CVD, cardiovascular disease; DM-1, DM-2, diabetes mellitus types 1 and 2; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; ENT, ear, nose, and throat; ESRD, end-stage renal disease; LFTs, liver function tests; NET, neutrophil extracellular trap; PASC, post-acute sequelae of SARS-CoV-2 infection; PE, pulmonary embolism; POTS, postural orthostatic tachycardia syndrome; TF, tissue factor; vWF, von Willebrand factor.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts